Cefditoren
From Wikipedia, the free encyclopedia
Cefditoren
|
|
Systematic (IUPAC) name | |
(2,2-dimethylpropanoyloxymethyl (6R,7R)-7-([(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino)-3 -[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
Chemical data | |
Formula | C25H28N6O7S3 |
Mol. mass | 620.721 g.mol-1 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Contents |
[edit] Clinical use
[edit] Indications
Cefditoren is used to treat uncomplicated skin and skin structure infections. community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis (ABECB), pharyngitis, tonsillitis, and
[edit] Formulations
Cefditoren is available as 200 mg tablets.
trade name: Spectracef, Ceftorin
[edit] See also
[edit] External links
|